CG Oncology is a clinical-stage immuno-oncology company focused on the development of oncolytic immunotherapies to combat cancer. The company's CG0070 has completed an investigation in a Phase II for patients with NMIBC who failed BCG therapy. In addition, CG Oncology is exploring the use of CG0070 in combination with immune checkpoint inhibitors in different solid tumors.
View Top Employees from CG Oncology| Website | http://www.cgoncology.com |
| Revenue | $7 million |
| Funding | $92.6 million |
| Employees | View employees |
| Address | 400 Spectrum Center Dr, Ste 2040, Irvine, California 92618, US |
| Technologies |
JavaScript,
HTML,
Google Analytics
+11 more
(view full list)
|
| Industry | Biotechnology, Pharmaceuticals, Healthcare |
| SIC | SIC Code 80 Companies, SIC Code 28 Companies, SIC Code 283 Companies |
| NAICS | NAICS Code 32 Companies, NAICS Code 3254 Companies, NAICS Code 325 Companies |
Looking for a particular CG Oncology employee's phone or email?
CG Oncology Questions
The CG Oncology annual revenue was $7 million in 2024.
CG Oncology is based in Irvine, California.
The NAICS codes for CG Oncology are [32, 3254, 325].
The SIC codes for CG Oncology are [80, 28, 283].
